Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JL15003 in Recurrent Glioblastoma
NCT07497373Phase 1Completed
- Sponsor
- Jecho Biopharmaceuticals Co., Ltd.
- Start
- Nov 2022
- Primary completion
- May 2024
- Modality
- Oncolytic Viruses
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of JL15003 in glioblastoma multiforme (GBM), sponsored by Jecho Biopharmaceuticals Co., Ltd. Primary endpoints: Incidence and severity of adverse events at 180 months, Dose limiting toxicity at 28 days and 1 more. Started Nov 2022; status: completed.
02
Drugs
JL15003
03
Conditions
glioblastoma multiforme (GBM)
Beyond the preview
Go deeper on NCT07497373.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07497373.